Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 9CNS 5Genitourinary 4Gastrointestinal 4Thoracic 2Gynecologic 2Breast 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Peritoneal Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Fallopian Tube Neoplasms 2Recurrence 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Paclitaxel 581Carboplatin 527Cisplatin 355Bevacizumab 256pembrolizumab 226Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 126Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 90niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 73Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 56Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
epothilone B × Gynecologic × Clear all
NCT00262990 2020-12-17

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Novartis

Phase 3 Completed
829 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

NCT00035100 2012-04-16

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Novartis

Phase 2 Completed
54 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡